×

Biotech and Pharmaceuticals Life Sciences

  • *Late-stage trial meets main goal. June 27- Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low. While the reduction in monthly migraine days looked "just ok", potentially...

  • *MYSTIC lung cancer trial results expected any day. *U.S. near-term put contracts outweigh call options 3.3 times. LONDON/ NEW YORK, June 27- Investors in drugmaker AstraZeneca have taken defensive positions in the options market ahead of eagerly awaited results of a major trial of a lung cancer treatment, which are due any day now.

  • *Late-stage study meets main goal. June 27- Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investors' expectation, sending its shares plunging as much as 26 percent to a more than two-and-half year low. The mean reduction looked slightly numerically lower than other CGRP trials,...

  • June 27- Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investors' expectation, sending its shares down about 23 percent in premarket trading on Tuesday. Patients receiving a 300 mg quarterly dose of the company's drug, eptinezumab, through infusion, experienced a reduction of...

  • June 27- Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectation, sending its shares about 20 percent in premarket trading on Tuesday. In the study, patients receiving a 300 mg dosage of the company's drug, eptinezumab, experienced a reduction of 4.3 days from...

  • June 27- Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study. Patients given the company's drug, eptinezumab, experienced a statistically significant reduction in monthly migraine days in both 300 mg and 100 mg dosages.

  • NEW YORK, June 26- Martin Shkreli, the pharmaceutical entrepreneur vilified as the "pharma bro" for raising the price of a life-saving drug by 5,000 percent, will go on trial on Monday for what U.S. prosecutors called a Ponzi-like scheme at his former hedge fund and a drug company he once ran. District Judge Kiyo Matsumoto in Brooklyn, is expected to last four to six...

  • Health care stocks led the market higher, continuing their strong recent run, after the Senate released its proposal to revamp how Americans get medical care. Benchmark U.S. crude rose 28 cents, or 0.7 percent, to $42.81 per barrel. Brent crude, the international standard, added 45 cents, or 1 percent, to $45.27.

  • *Britain and Germany still ahead in the field. PARIS, June 15- France's corporate startup scene is gaining traction against the backdrop of booming investments by venture capital funds and high expectations for a business friendly government under new President Emmanuel Macron. The new president, who plans a raft of other measures start-u boosting measures...

  • *Britain and Germany still ahead in the field. PARIS, June 15- France's corporate startup scene is gaining traction against the backdrop of booming investments by venture capital funds and high expectations for a business friendly government under new President Emmanuel Macron. This taxpayer financing is 13 percent higher than the previous year and...

  • Trump may be the best thing that ever happened to the planet

    Trump's withdrawal from Paris agreement will motivate the private sector to take over where government is falling short.

  • JERUSALEM, June 7- Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraines cleared another late-stage study, setting it on course for U.S regulatory approval and launch in the second half of 2018.. Analysts have estimated it could generate at least $1 billion in sales annually. "Teva plans to submit a Biologics License...

  • DNA study maps genetic code to rethink human aging

    J. Craig Venter, Human Longevity Inc., explains how gathering massive amounts of data is helping to pioneer advances in genome studies and contribute to changing the way scientist think about health and aging.

  • CHICAGO, June 7- Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world's biggest annual oncology meeting. Investors had been closely watching the fortunes of CAR-T developers, including Kite Pharma Inc and...

  • Juno, which earlier this year gave up on developing CAR-T candidate JCAR015 for acute lymphoblastic leukemia after toxicities and patient deaths, presented early trial results at a meeting in Chicago of the American Society for Clinical Oncology for another candidate, JCAR017, as a treatment for non-Hodgkin lymphoma. "They needed to hit a grand slam home run...

  • Cramer Remix: What Chipotle’s past can tell you about Wells Fargo’s future

    Wells Fargo might not serve salsa, but Jim Cramer pointed out the two stocks have more in common than you might think.

  • *FDA backs 21 new drugs this year vs 22 for whole of 2016. LONDON, May 25- The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.

  • LONDON, May 22- AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Data from the 28- week Phase III clinical trial presented at the American Thoracic Society on Monday...

  • *Sees 2017 adjusted earnings of 4.4 bln- 4.6 bln euros. The family-controlled firm said on Thursday that sales of its performance materials would fall slightly in 2017, after adjusting for currency swings, having previously forecast growth for the division that is the world's leading supplier of liquid crystals ahead of Japan's JNC Corp and DIC Corp..

  • According to the FDA approval letter, the company has until December to submit the full trial data to the agency. Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer. In addition to Tecentriq's approval for bladder cancer patients whose disease has...